Andrew X Zhu, MD, PhD

Biography

Dr. Andrew X. Zhu has served as the President of IMAB and TJ Biopharma, Director of Jiahui International Cancer Center and Chief Scientific Officer of Jiahui International Hospital, and Honorary Professor at Zhongshan Hospital, Fudan University. He is also the Director Emeritus of Liver Cancer Center at Massachusetts General Hospital Cancer Center and former Professor of Medicine at Harvard Medical School. The major focus of his research is to develop more effective therapies for hepatocellular carcinoma (HCC) and cholangiocarcinoma, and drug development.

An internationally recognized authority in HCC and cholangiocarcinoma, he led early efforts of developing several molecularly targeted, immunotherapeutic agents, and combination regimens in liver cancers and studying the predictive and surrogate molecular and imaging biomarkers. He and his colleagues initially identified the presence of IDH mutations and the resistance mechanism to FGFR inhibitors in cholangiocarcinoma. As the lead global principal investigator, he led the pivotal studies which led to the regulatory approval of pembrolizumab and ramucirumab in advanced HCC and ivosidenib in IDH-1 mutant cholangiocarcinoma.